A Study of ABL001 in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b/2 multi-center study to assess the safety, tolerability,
pharmacokinetics of ABL001 in combination with Irinotecan or Paclitaxel in patients with
advanced or metastatic solid tumors.